Vladimir Fridman, MD
Cardiovascular Disease · Brooklyn, NYNPI 1538343595
Payments from drug & device makers
Across 203 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$708
- Johnson & Johnson$454
- Boston Scientific$388
- Merck$378
- Amarin Pharma, Inc.$336
- E.r. Squibb & Sons, L.L.C.$263
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,876100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 32 | $708 |
| Johnson & Johnson(2 entities) | 12 | $454 |
| Boston Scientific | 10 | $388 |
| Merck | 20 | $378 |
| Amarin Pharma, Inc. | 16 | $336 |
| E.r. Squibb & Sons, L.L.C. | 12 | $263 |
| AbbVie | 13 | $256 |
| Novartis | 15 | $233 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $225 |
| Lilly USA, LLC | 4 | $193 |
| Aimmune Therapeutics, Inc. | 1 | $146 |
| AstraZeneca | 6 | $145 |
| Heartflow, Inc. | 6 | $132 |
| Sanofi-aventis U.S. LLC | 5 | $128 |
| Biotronik Inc. | 1 | $116 |
| Pfizer | 5 | $112 |
| Otsuka America Pharmaceutical, Inc. | 4 | $98 |
| Kowa Pharmaceuticals America, Inc. | 5 | $93 |
| Sumitomo Pharma America, Inc. | 5 | $82 |
| Abbott | 2 | $66 |
| Axsome Therapeutics, Inc. | 3 | $63 |
| Lundbeck LLC | 2 | $50 |
| Novo Nordisk | 2 | $40 |
| Impel Pharmaceuticals Inc. | 2 | $35 |
| Ardelyx, Inc. | 1 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Nalpropion Pharmaceuticals LLC | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$241
- ZENPEP$146
- JARDIANCE$125
- Orsiro Mission$116
- DYNAGEN$106
How this compares
$4,876 in reported general payments places this provider in the 70th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 665 | $450,593 |
| ZenpepLipase/Protease/Amylase | 260 | $373,730 |
| Diclofenac Sodium | 825 | $340,064 |
| LinzessLinaclotide | 436 | $230,346 |
| OzempicSemaglutide | 170 | $158,283 |
| UbrelvyUbrogepant | 100 | $153,511 |
| VascepaIcosapent Ethyl | 473 | $148,738 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 112 | $140,146 |
| MounjaroTirzepatide | 131 | $136,114 |
| CreonLipase/Protease/Amylase | 154 | $114,850 |
| JubliaEfinaconazole | 71 | $114,487 |
| Nurtec OdtRimegepant Sulfate | 69 | $104,183 |
| LofenaDiclofenac Potassium | 34 | $97,724 |
| MyrbetriqMirabegron | 203 | $90,764 |
| JanuviaSitagliptin Phosphate | 101 | $67,284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Ubrelvy, Creon, Restasis, Namzaric | $256 | $639,218870 claims |
| PfizerEliquis, Nurtec Odt | $112 | $554,776734 claims |
| Aimmune Therapeutics, Inc.Zenpep | $146 | $373,730260 claims |
| Lilly USA, LLCMounjaro, Trulicity | $193 | $184,593183 claims |
| Novo NordiskOzempic | $40 | $158,283170 claims |
| MerckJanuvia, Janumet | $378 | $112,146181 claims |
| Boehringer IngelheimJardiance, Tradjenta | $16 | $65,830120 claims |
| Johnson & JohnsonXarelto | $454 | $64,003105 claims |
| NovartisEntresto | $233 | $42,76565 claims |
| AstraZenecaFarxiga | $145 | $32,09737 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $82 | $29,44761 claims |
| Ardelyx, Inc.Ibsrela | $28 | $27,93616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Brooklyn
- Ronald WhartonBrooklyn$1.1M
- Ozgen DoganBrooklyn$404K
- Warren WexelmanBrooklyn$396K
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.